Groups urge Fed Circ to rehear Biogen patent case
18-01-2022
Biogen sues Teva over MS generic
18-03-2021
Mylan launches Tecfidera generic amid Biogen battle
20-08-2020
Formatoriginal / Shutterstock.com
The US Court of Appeals for the Federal Circuit has refused Biogen’s attempt to revive a key patent for its multiple sclerosis drug Tecfidera (dimethyl fumarate), leaving Mylan’s successful challenge intact.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
fumarate, dimethyl, Federal, Circuit, Mylan, OMalley, Tecfidera, Biogens, dissent, Reyna, generic, description, court, claims, patent, infringement
